Jasper Therapeutics Stock - Analyst consensus and weekly review

Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 20:55 UTC. Details in the imprint.

Jasper Therapeutics (US47191J1060) is drawing attention mainly for its analyst coverage and recent trading pattern rather than fresh headlines today. On this quiet news day, the focus shifts to how Wall Street values the small-cap biotech and how it compares with its peers.

What analysts say about JSPR

Jasper Therapeutics is covered by only a handful of Wall Street firms, reflecting its early-stage pipeline and limited revenue base. According to consensus data compiled by MarketWatch, the stock carries a predominantly Buy rating profile with a speculative risk tag.

Price targets cluster well above the current market price, illustrating the typical biotech pattern where analyst models discount the potential value of future clinical milestones. Against this backdrop, investors often focus less on absolute target levels and more on rating changes or revised assumptions.

How the stock compares with peers

In the broader small-cap cell and gene therapy space, companies without late-stage assets or near-term revenue often trade with high volatility and sharp reactions to data updates. Jasper Therapeutics sits in this group alongside several pre-commercial developers on Nasdaq.

The company’s market value remains modest compared with larger hematology and oncology peers, underlining both the upside optionality and the funding risk typical for clinical-stage biotech. For many investors, capital structure and cash runway are therefore as important as pipeline news.

How the company makes money

Jasper Therapeutics focuses on biologic therapies designed to condition the bone marrow ahead of hematopoietic stem cell transplantation and to treat immune and blood disorders. As a clinical-stage biotech, it currently generates little to no product revenue and funds operations mainly through equity and partnerships.

Where the stock trades today

Jasper Therapeutics shares (US47191J1060) trade on Nasdaq at around $3.00 as of 06/19/2026, 20:55 UTC.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.